Posted on March 7th, 2014 by Margaret Shepard
A group of pediatric gastroenterologists are using an iPad application to track patients' symptoms. This app tries to enhance the communication between the doctor and the patient. The patients get an automated response when to take their medication and also tries to track their symptoms if there are side effects to the medication, stress triggers, or food triggers. This app feeds the information back to the doctor's office to help make the best decisions for the patient.
The Oklahoma Medical Center and the Mayo Clinic are working on a iPad quiz game app. When patients visit the doctor's office, [...]
Posted on March 5th, 2014 by Margaret Shepard
Michael Stephens, M. D., discusses a recent study published in the Inflammatory Bowel Diseases Journal about the drug methotrexate and the possibility of liver toxicity. This project was done in Toronto, Canada at the Hospital for Sick Children.
Methotrexate is an immune modulating drug used to treat inflammatory bowel diseases, particularly Crohn's disease. One of the side effects of taking methotrexate is liver toxicity. The researchers of this study looked at all the data of children who took methotrexate to create a large pool of patients and analyzed how often liver toxicity happened. By looking at the all the data, the researchers were able to find the evidence of liver irritation to be about 10%. In a little [...]
Posted on February 27th, 2014 by Margaret Shepard
Sunanda Kane, M. D., discusses recent articles published in the Journal of Pediatric Psychology and Inflammatory Bowel Disease Journal about medication adherence for children and adults with ulcerative colitis.
The first article focuses on pediatric patients and whether or not parents could predict how much medication their children were taking. This study looked for a correlation between what children and parents were saying in terms of how much medication they were taking and what electronic caps on the medicine were counting. Children in the study were sent home with medication that had an electronic cap on it that sent a signal every time it was opened to generally reflect pill taking behavior. The results from the study show that parents [...]
Posted on February 25th, 2014 by Margaret Shepard
Sunanda Kane, M. D., discusses a recent paper published in the Gastroenterology Journal about the risks of birth defects in women who have inflammatory bowel disease. One of the most important questions a woman has when thinking about having children is will her inflammatory bowel disease increase the risk for birth defects.
There has been conflicted data in recent studies about inflammatory bowel disease causing birth defects. This study, published in the United Kingdom, looks at all women with inflammatory bowel disease throughout the United Kingdom from 1990 to 2010 and assess whether or not their children have a birth defect. In addition, the study assessed the mother's health in terms of if she was a smoker, the age when [...]
Posted on February 19th, 2014 by Margaret Shepard
Ed Loftus, M. D., discusses a recent study published in The American Journal of Gastroenterology that examines if medications after surgery can effectively prevent reoccurrence of Crohn's disease. Many patients find surgery to be beneficial in managing quality of life if they have obstructive symptoms, but many patients will have recurring symptoms.
This study took place in Italy and examined 51 patients randomized into three groups. All of the patients had undergone an ileocolonic resection for their Crohn's disease. Group one received adalimumab at 160 mg baseline, 80 mg 2 weeks later, and then 40 mg every 2 weeks. Group two received azathioprine at 2 mg per 1 kg of body weight. Group three received 3 g daily of mesalamine. The patients [...]
Posted on February 12th, 2014 by Margaret Shepard
Purna Kashyap, M.D., discusses a recent study published in Nature that focuses on how short-term diet changes may influence what gut microbes are present. Long-term diet patterns can influence an individual’s gut microbiome.
The study focuses on short-term diet changes of either a plant-based diet or animal-based diet. The results found a shift of what gut microbes were present and what they were doing at a given point in time. Dr. Kashyap says the study provides hope for the future that diet may in fact be a major player as a therapeutic agent to treat IBD itself or flares of the disease that may occur.
The full text of the study can be found here.
For more information [...]
Posted on February 11th, 2014 by Margaret Shepard
Ed Loftus, M.D., discusses recent developments on a drug, vedolizumab, that is currently being reviewed by the Food and Drug Administration for inflammatory bowel disease. Vedolizumab is thought to be more gut specific and potentially have fewer adverse side effects.
In December, an advisory committee convened by the FDA met to review all the data and recommend whether vedolizumab should be used to treat ulcerative colitis and Crohn's disease. The committee was reviewing if the drug would cause progressive multifocal leukoencephalopathy (PML), a serious neurological condition. Since the drug is gut specific, it doesn't appear to affect the blood brain barrier. Over 3,000 patients have been treated with this drug and there have not been any cases of PML.
Posted on February 4th, 2014 by Margaret Shepard
Jeanne Tung, M.D., discusses a recent study published in the Journal of the American Medical Association that tested the effects of thalidomide in children and adolescents with refractory Crohn’s disease.
After eight weeks, the patients that received thalidomide did better than the patients that received the placebo. Patients that had clinical remission from taking thalidomide were able to use this drug for 2-4 years. Some patients that lost response or had reactions to remicade did respond to thalidomide. This small clinical trail shows that patients with Crohn’s may benefit from taking thalidomide.
There are three major side effects to taking thalidomide: